Profile data is unavailable for this security.
About the company
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company develops and manufactures a range of pharmaceutical products for the Indian and international markets. In the international market, it has tie-ups with generic companies across the globe. It has approximately eight domestic marketing divisions, with a brand portfolio in various therapeutic segments including gastro-intestinal, respiratory, anti-infective, stomatologicals, ophthalmic, nutritionals, cardiovascular, anti-diabetics, pain management, gynecology and others. The Company's brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral and Rexidin. The Company has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.
- Revenue in INR (TTM)17.73bn
- Net income in INR320.40m
- Incorporated1947
- Employees5.93k
- LocationIndoco Remedies Ltd166 Indoco HouseCst Road, Santacruz EastMUMBAI 400098IndiaIND
- Phone+91 2 226541851
- Fax+91 2 226523980
- Websitehttps://www.indoco.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zota Health Care Ltd | 1.98bn | -242.34m | 16.03bn | 445.00 | -- | -- | 3,431.57 | 8.09 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Sigachi Industries Ltd | 4.10bn | 594.65m | 16.44bn | 991.00 | 30.75 | -- | 23.11 | 4.01 | 1.60 | 1.60 | 10.97 | -- | -- | -- | -- | 4,136,886.00 | -- | 14.77 | -- | 19.57 | 52.33 | 50.30 | 14.43 | 14.92 | -- | 7.19 | -- | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| Beta Drugs Ltd | 2.96bn | 364.37m | 18.43bn | 371.00 | 50.57 | 11.73 | 39.86 | 6.23 | 37.90 | 37.90 | 307.59 | 163.43 | 1.31 | 4.51 | 4.17 | 7,970,723.00 | 16.10 | 15.10 | 23.91 | 22.23 | 38.73 | 39.77 | 12.32 | 12.38 | 1.51 | 17.81 | 0.0654 | 0.00 | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
| Syncom Formulations (India) Ltd | 2.91bn | 285.50m | 18.99bn | 802.00 | 61.97 | -- | 56.73 | 6.53 | 0.326 | 0.326 | 2.99 | -- | -- | -- | -- | 3,626,019.00 | -- | 7.50 | -- | 10.23 | 39.53 | 34.10 | 9.82 | 9.38 | -- | 7.67 | -- | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Hester Biosciences Ltd | 3.12bn | 234.69m | 20.03bn | 642.00 | 82.98 | 6.64 | 47.55 | 6.41 | 28.37 | 28.37 | 368.62 | 354.81 | 0.4617 | 1.22 | 3.23 | 4,862,882.00 | 3.89 | 6.15 | 4.91 | 7.69 | 71.13 | 66.64 | 8.42 | 12.83 | 1.22 | 2.85 | 0.4371 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| Panacea Biotec Ltd | 5.46bn | -279.53m | 20.30bn | 1.15k | -- | -- | 267.27 | 3.72 | -4.58 | -4.58 | 89.84 | -- | -- | -- | -- | 4,761,763.00 | -- | 10.26 | -- | 16.53 | 60.24 | 50.27 | -5.20 | 24.87 | -- | -17.30 | -- | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Amrutanjan Health Care Ltd | 4.27bn | 425.73m | 21.96bn | 635.00 | 51.67 | -- | 44.98 | 5.14 | 14.71 | 14.71 | 147.56 | -- | -- | -- | -- | 6,726,040.00 | -- | 16.22 | -- | 20.12 | 49.61 | 53.09 | 9.97 | 13.23 | -- | 212.51 | -- | 18.95 | 10.96 | 10.71 | 12.90 | 12.46 | 26.93 | 16.43 |
| Windlas Biotech Ltd | 6.61bn | 596.01m | 23.32bn | 1.15k | 39.12 | -- | 30.66 | 3.53 | 28.52 | 28.52 | 316.58 | -- | -- | -- | -- | 5,730,702.00 | -- | -- | -- | -- | 37.39 | -- | 9.01 | -- | -- | 48.16 | -- | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 23.54bn | 2.78k | 19.85 | -- | 12.73 | 1.14 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| Themis Medicare Ltd | 4.20bn | 529.90m | 24.11bn | 1.54k | 45.53 | 5.85 | 37.67 | 5.73 | 5.75 | 5.75 | 45.63 | 44.76 | 0.7306 | 2.39 | 2.22 | 2,727,670.00 | 9.21 | 11.12 | 12.57 | 16.46 | 64.64 | 60.32 | 12.61 | 14.96 | 1.56 | -- | 0.1651 | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| SMS Pharmaceuticals Ltd | 7.38bn | 569.64m | 24.93bn | 1.20k | 43.63 | -- | 28.02 | 3.38 | 6.75 | 6.75 | 87.48 | -- | -- | -- | -- | 6,168,549.00 | -- | 5.43 | -- | 7.33 | 30.12 | 33.30 | 7.69 | 7.87 | -- | 4.21 | -- | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Indoco Remedies Ltd | 17.73bn | 320.40m | 28.60bn | 5.93k | 93.03 | 2.63 | 20.98 | 1.61 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| Dishman Carbogen Amcis Ltd | 24.16bn | -2.48bn | 30.54bn | 1.13k | -- | -- | 176.82 | 1.26 | -15.81 | -15.81 | 154.06 | -- | -- | -- | -- | 21,344,260.00 | -- | -0.3986 | -- | -0.4888 | 79.30 | 73.83 | -10.27 | -1.54 | -- | -0.7216 | -- | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
| RPG Life Sciences Limited | 6.00bn | 923.20m | 41.48bn | 1.27k | 44.93 | -- | 37.55 | 6.92 | 55.82 | 55.82 | 362.60 | -- | -- | -- | -- | 4,721,969.00 | -- | 16.07 | -- | 21.77 | 68.42 | 62.99 | 15.39 | 11.99 | -- | 220.43 | -- | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
Data as of Nov 01 2024. Currency figures normalised to Indoco Remedies Ltd's reporting currency: Indian Rupee INR
17.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 2024 | 4.58m | 4.97% |
| quant Money Managers Ltd.as of 30 Sep 2024 | 4.20m | 4.56% |
| DSP Asset Managers Pvt. Ltd.as of 30 Sep 2024 | 2.34m | 2.54% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 2024 | 1.54m | 1.67% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Sep 2024 | 1.36m | 1.48% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2024 | 1.05m | 1.14% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 631.89k | 0.69% |
| Tata Asset Management Pvt Ltd.as of 30 Sep 2024 | 366.99k | 0.40% |
| Fiduciary Management, Inc.as of 31 Aug 2024 | 165.42k | 0.18% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 22.75k | 0.03% |
More ▼
Data from 30 Jun 2024 - 24 Oct 2024Source: FactSet Research Systems Inc.
